US EditionAstraZeneca beats profit expectations on robust drug sales, US demand
GREATER LONDON, ENGLAND, JUL 29 – AstraZeneca reported 11% revenue growth to $14.46 billion driven by cancer drug sales and a 13% rise in U.S. revenue despite tariff and pricing challenges.
- On Tuesday , AstraZeneca beat second-quarter profit expectations, with net profit rising 27% and maintaining its annual outlook while raising its interim dividend.
- Last month, AstraZeneca's revenue reached $14.46 billion, with core earnings of $2.17 per share, amid sector pricing challenges and US tariffs.
- Revenue grew 11% to $14.46 billion, with the US market accounting for half and surging 18%.
- The boost comes as the sector braces for US tariffs and pricing challenges after Trump's order pushing for prices to fall, according to analysts.
- The company aims to reach $80 billion in annual revenue by 2030, targeting 20 new medicines and shifting focus from China probes to the US footprint.
Insights by Ground AI
Does this summary seem wrong?
Podcasts & Opinions
18 Articles
18 Articles
AstraZeneca beats profit expectations on robust drug sales, US demand
AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines and strong demand in the U.S., where it has invested $50 billion to expand amid tariff threats from Washington.
·United Kingdom
Read Full Article
AstraZeneca beats second-quarter profit expectations
AstraZeneca has today beaten second-quarter profit forecastson robust sales of cancer, heart and kidney disease drugs and strong demand in the US, where it has invested $50 billion to expand amid tariff threats from President Donald Trump.
·Ireland
Read Full ArticleCoverage Details
Total News Sources18
Leaning Left2Leaning Right0Center7Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
L 22%
C 78%
Factuality
To view factuality data please Upgrade to Premium
